Aditxt, Inc. Files 8-K with Regulatory Disclosures
Ticker: ADTX · Form: 8-K · Filed: Apr 7, 2025 · CIK: 1726711
Sentiment: neutral
Topics: 8-K, regulatory-disclosure, financials
TL;DR
Aditxt filed an 8-K on 4/4/25 covering Reg FD and financials. Formerly Aditx Therapeutics.
AI Summary
On April 4, 2025, Aditxt, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Aditx Therapeutics, Inc., is incorporated in Delaware and headquartered in Mountain View, California.
Why It Matters
This filing provides important updates and financial information for investors and stakeholders of Aditxt, Inc., ensuring transparency in its corporate activities.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K report, not indicating any specific new risks or material adverse events.
Key Players & Entities
- Aditxt, Inc. (company) — Registrant
- Aditx Therapeutics, Inc. (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- Mountain View, CA (location) — Principal executive offices
- April 4, 2025 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing by Aditxt, Inc.?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on April 4, 2025.
What were Aditxt, Inc.'s former names?
Aditxt, Inc. was formerly known as Aditx Therapeutics, Inc. and ADiTx Therapeutics, Inc.
In which state is Aditxt, Inc. incorporated?
Aditxt, Inc. is incorporated in Delaware.
Where are Aditxt, Inc.'s principal executive offices located?
Aditxt, Inc.'s principal executive offices are located at 2569 Wyandotte Street, Suite 101, Mountain View, CA 94043.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 7, 2025 regarding Aditxt, Inc. (ADTX).